Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use
AP (AP Photo/Matt Rourke, File)
US president Donald Trump and tech billionaire Elon Musk appear to be drifting apart after a series of high-profile moves involving their close associates, political roles, and a damaging media report. Trump withdrew his pick of Jared Isaacman to lead NASA, while Musk exited his advisory role in the Department of Government Efficiency (DOGE).
Trump pulls Isaacman's NASA nomination
Trump on Saturday said he was rescinding the nomination of Isaacman, a private astronaut and payments entrepreneur, to head the US space agency.
'After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA,' Trump wrote on his Truth Social platform. 'I will soon announce a new Nominee who will be Mission aligned, and put America First in Space.' Isaacman, founder of Shift4 Payments, has worked closely with Musk's SpaceX and is known for leading the first all-civilian space mission. His ties to Musk reportedly played a key role in his nomination. The New York Times reported that Trump decided to pull back after learning that Isaacman had previously donated to well-known Democratic candidates.
Responding to that report, the White House told AFP in an email, 'It is essential that the next leader of NASA is in complete alignment with president Trump's America First agenda. The Administrator of NASA will help lead humanity into space and execute president Trump's bold mission of planting the American flag on the planet Mars.'
Musk leaves DOGE amid growing scrutiny
Appointed by the president himself, Musk became in-charge of DOGE, a key project aimed at cutting government spending. His appointment made headlines and sparked strong reactions from both supporters and critics.Although many expected Musk to step down, his exit came shortly after he publicly disagreed with parts of Trump's policy plans. That added to growing concerns about his role in Washington.During his time at DOGE, Musk pushed for major spending cuts. Several government agencies were shut down and thousands of jobs were cut. These changes led to public protests and raised questions about whether it was appropriate for someone running large private companies to be involved in such decisions.While Musk led DOGE, his companies, including Tesla, SpaceX and Neuralink, continued to operate, Tesla shares fell sharply, and protests erupted following DOGE's sweeping budget cuts and the closure of several federal agencies.
Musk denies drug use claims by NYT
Meanwhile, Musk hit back at a New York Times report that accused him of regular drug use during the 2024 campaign period.The newspaper reported that Musk had used ketamine, ecstasy, and mushrooms and even developed bladder issues from frequent ketamine use. It said he carried a pill box and it was unclear whether he continued using drugs after joining the Trump administration in January.Musk rejected the claims on Saturday. 'To be clear, I am NOT taking drugs. The New York Times was lying their ass off,' he wrote on X.He added, 'I tried 'prescription' ketamine a few years ago and said so on X, so this is not even news. It helps for getting out of dark mental holes, but haven't taken it since then.'When asked by a reporter if he knew about Musk's alleged drug use, Trump replied, 'I wasn't. I think Elon is a fantastic guy.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
17 minutes ago
- Mint
Over 1,800 people arrested in crack down on Asia-based scam operations
HONG KONG (AP) — More than 1,800 people have been arrested in a joint operation across Asia targeting scam networks, police in Hong Kong said on Tuesday. The crack down involving authorities in six other jurisdictions successfully intercepted fraudulent funds involving about $20 million, Wong Chun-yue, chief superintendent of the city's police's commercial crime bureau, said. The scam networks were closed down during the operation jointly conducted by South Korea, Thailand, Singapore and neighboring Chinese gambling hub Macao, he said. The operation, which also involved authorities from Malaysia and the Maldives, targeted cases of online shopping and telephone scams, as well as investment and employment frauds. Nearly 33,000 accounts were frozen in the month to May 28, Wong said. Those arrested were aged between 14 and 81. In one case in March, a finance director in Singapore was scammed through deep-fake videos by someone who claimed to be the chief executive at a multinational corporation. The victim transferred $499,000 to Hong Kong, said Aileen Yap, assistant director of Singapore police's anti-scam command. Through cross-border cooperation, the money was recovered, she said. The victims of scams and online fraud often include not only those defrauded but also the workers used by scamming operations, with staff facing threats, violence and poor working conditions. A United Nations report in April found transnational organized crime groups in East and Southeast Asia are spreading their scam operations across the globe. For several years, scam compounds have proliferated in Southeast Asia, especially in border areas of Cambodia, Laos and Myanmar, as well as in the Philippines, shifting operations from site to site to stay a step ahead of the police, according to the report issued by the U.N. Office on Drugs and Crime.
India Gazette
18 minutes ago
- India Gazette
Trump's revised 50% tariff on steel a severe blow to Korean exporters
New Delhi [India], June 3 (ANI): South Korea, the fourth-largest steel supplier to the US, is likely to face a severe blow from the US decision to double tariffs on imported steel and aluminium from 25 per cent to 50 per cent, starting reported by the Korea Herald, Trump described the move as a deal that would 'secure' the American steel industry, one that 'nobody's going to get around.'As per government data, in 2024, exports to the US accounted for 13 per cent of Korea's total steel industry insider told Korea Herald, 'At a time when exports to the US are barely holding up following the 25 per cent tariff, an additional 25 per cent will severely undermine the competitiveness of Korean companies.'In response to the US decision to raise tariffs to 50 per cent, Korean trade officials and steelmakers, including Posco Holdings and Hyundai Steel, held an emergency meeting on Monday, convened by the Ministry of Trade, Industry and Energy in Seoul to assess the to a Seoul-based market researcher at Daol Investment & Securities, even after the initial 25 per cent tariff, US prices for hot-rolled steel remained high. 'The full impact of the new hike depends on how much US steel prices rise in response,' the researcher in turn, may increase the competitive edge of companies like Hyundai Steel. The company is committed to a USD 5.8 billion investment plan to build an electric arc furnace-based integrated steel mill in Louisiana by 2029, in partnership with Posco the US President, Donald Trump, endorsed US Steel's USD 14 billion acquisition by Japan-based Nippon Steel, a deal he had previously opposed on national security grounds. And he said the partnership would create and save more than 100,000 jobs while keeping the American steelmaker under US control, though few details have been disclosed. (ANI)
India Gazette
19 minutes ago
- India Gazette
Trump's Executive Order on reducing prescription drug prices will have limited impact on Indian pharma companies: Crisil Ratings
New Delhi [India], June 3 (ANI): US President Donald Trump's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies, according to a report by Crisil Ratings. Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. In over half of the pharmaceutical output, one-third goes to the United States. India exports 54 per cent of its pharmaceutical production, of which nearly a third is to the US. Around 85 per cent of the exports to the US comprise formulations, largely generics, while sales from biosimilars and innovator drugs remain low. Generic pharma drugs account for 90 per cent of the prescription sales volume but only 13 per cent of the value spending in the US. Generic drug prices in the US are very low and have lower prices in comparison to economically peer countries. The executive order issued in the United States aims to reduce the prices of prescription drugs by 30-80 per cent through the adoption of a Most Favoured Nation (MFN) pricing model. The US Department of Health and Human Services (HHS) has outlined the initial steps to be taken to implement this policy, involving identification of manufacturers expected to align the prices of branded products, which do not currently have generic or biosimilar competition, with the lowest price among a set of economic peer countries of the US. Trump's executive order primarily targets high-margin branded innovator drugs and excludes generics and biosimilars. 'The MFN model is unlikely to significantly affect the bulk of India's exports,' the report added. It further added, 'However, potential indirect impact, through lower growth prospects for upcoming generic versions of innovator drugs going off patent, due to lower price differential post price reductions of the innovator drugs, would bear watching.' However, a few formulation companies with niche presence in the branded innovator drug segment can face some pricing risk. 'API exports (15 per cent of India's pharma exports) are expected to be broadly unaffected, as it is not a major cost for high-margin originator drugs, abating concerns of pricing pressure,' the report added. Additionally, the policy may create opportunities for contract manufacturing organisations, which constitute 8 per cent of India's pharma market. 'The policy may create opportunities for CMOs ( 8 per cent of India's pharma market), with orders expected to improve as global pharma companies seek to lower production costs by outsourcing. While this could support volumes, the pressure on pricing may result in renegotiation of contract rates, compressing margins,' the report further added. (ANI)
